A Study on Modified Endoscopic Mucosal Resection in Rectal Neuroendocrine Tumors

Objective: To explore the clinical feasibility and safety of modified endoscopic mucosal resection for rectal neuroendocrine tumors (R-NETs). Methods: Seventy cases of R-NETs treated with endoscopic mucosal resection in our hospital between April 2022 and March 2024 were selected and divided into the control group and the observation group using the mean score method, each with 35 cases. In the control group, traditional endoscopic mucosal resection (EMR) was performed, and in the observation group, modified EMR (endoscopic mucosal resection with ligation apparatus [EMR-L]) was performed. The operation time, hospitalization time, operation cost, and related complication rate of the two groups of patients were compared. Results: The operation time (20.36 ± 1.46 min) and hospital stay (3.37 ± 0.51 d) of patients in the observation group were shorter than those of the control group (31.44 ± 2.65 min and 4.73 ± 0.49 d). The cost of the operation in the observation group (7,695.85 ± 1,521.42 yuan) was lower than that of the control group (8,418.62 ± 1219.30 yuan), and the difference was statistically significant (P < 0.05). The total incidence of postoperative related complications in the observation group was observed to be 11.42%, which was significantly lower than that of 31.42% in the control group, and the difference was statistically significant (P < 0.05). Conclusion: The application of modified EMR in R-NETs is remarkable, which can not only effectively shorten the operation time and hospital stay, but also further reduce the risk of related complications, and indirectly save a large amount of hospital costs; thus, it is recommended to be promoted and applied clinically.